Unum Therapeutics Inc (NASDAQ:UMRX)’s share price rose 8.1% during trading on Wednesday . The stock traded as high as $0.98 and last traded at $0.93, approximately 229,443 shares traded hands during trading. A decline of 26% from the average daily volume of 310,344 shares. The stock had previously closed at $0.86.
UMRX has been the subject of several recent analyst reports. Zacks Investment Research upgraded Unum Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a research report on Saturday, November 9th. Morgan Stanley dropped their price target on Unum Therapeutics from $8.00 to $3.00 and set an “overweight” rating for the company in a research report on Wednesday, November 27th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $8.30.
The firm has a market capitalization of $26.33 million, a P/E ratio of -0.68 and a beta of 1.02. The company has a quick ratio of 1.96, a current ratio of 1.96 and a debt-to-equity ratio of 0.17. The firm’s 50-day simple moving average is $0.73 and its 200-day simple moving average is $1.47.
Unum Therapeutics (NASDAQ:UMRX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.39) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.07). The company had revenue of $1.02 million during the quarter, compared to analysts’ expectations of $4.41 million. Unum Therapeutics had a negative return on equity of 96.07% and a negative net margin of 388.07%. As a group, analysts expect that Unum Therapeutics Inc will post -1.42 EPS for the current fiscal year.
Several institutional investors have recently bought and sold shares of the company. Paloma Partners Management Co bought a new stake in shares of Unum Therapeutics during the 2nd quarter worth $227,000. Jane Street Group LLC purchased a new position in Unum Therapeutics in the second quarter worth $132,000. Wedbush Securities Inc. purchased a new position in Unum Therapeutics in the third quarter worth $48,000. Susquehanna International Group LLP bought a new position in Unum Therapeutics in the second quarter valued at $62,000. Finally, Tower Research Capital LLC TRC bought a new position in Unum Therapeutics in the third quarter valued at $31,000. Hedge funds and other institutional investors own 40.34% of the company’s stock.
About Unum Therapeutics (NASDAQ:UMRX)
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).
Recommended Story: Pattern Day Trader
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.